Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03046407

Treatment of Dry Age Related Macular Degeneration Disease With Retinal Pigment Epithelium Derived From Human Embryonic Stem Cells

Sponsor: Chinese Academy of Sciences

Conditions Dry Age-related Macular Degeneration

Interventions retinal pigment epithelium transplantation

Updated 7 times since 2017 Last updated: Jan 30, 2018 Started: Sep 6, 2017 Primary completion: Jan 31, 2019 Completion: Dec 31, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Dry Age-related Macular Degeneration and is currently ongoing. Chinese Academy of Sciences leads this study, which shows 7 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2

Status: Recruiting → Unknown Status
Jun 2018 — Jan 2021 [monthly]

Recruiting PHASE1_PHASE2
Feb 2018 — Jun 2018 [monthly]

Recruiting PHASE1_PHASE2

Phase: EARLY_PHASE1 → PHASE1_PHASE2

▶ Show 2 earlier versions

May 2017 — Feb 2018 [monthly]

Recruiting EARLY_PHASE1
Feb 2017 — May 2017 [monthly]

Recruiting EARLY_PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chinese Academy of Sciences
The First Affiliated Hospital of Zhengzhou University

Data source: Chinese Academy of Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zhengzhou, China